Emyria Secures $8M to Launch First Victorian Empax Clinic and Expand Nationwide
Emyria Limited is fast-tracking its national rollout of Empax mental health clinics, backed by a strong $8 million institutional placement and new dual-payer funding pathways.
- Exercised option to establish first Empax clinic in Victoria’s Mornington Peninsula
- Expanded exclusive rights to roll out clinics across Avive Health’s national network
- Brisbane Empax Clinic begins generating insurer-funded revenue
- Department of Veterans’ Affairs initiates funding for medication-assisted psychotherapy
- Completed $8 million institutional placement to accelerate clinic rollout and workforce growth
Strategic Expansion into Victoria
Emyria Limited (ASX, EMD) has taken a significant step forward in its national expansion strategy by exercising its option to establish the first Empax clinic in Victoria, located within Avive Health’s flagship mental-health hospital in Mornington. This move marks a pivotal East Coast milestone, granting Emyria a six-month exclusive negotiation window to finalize commercial terms. The Mornington site is expected to become a cornerstone location, expanding the company’s reimbursed treatment footprint and reinforcing its first-mover advantage in intensive mental-health care.
Strengthened Partnership with Avive Health
Building on its existing collaboration, Emyria has secured exclusive rights to negotiate Empax clinic rollouts across all current and future Avive Health-operated hospitals nationwide. Avive currently operates four clinics with two more under construction, providing a scalable platform for Emyria’s capital-light expansion model. This enhanced agreement offers greater rollout certainty and operational flexibility, allowing Emyria to deploy its clinician-led, psychiatrist-supervised care model consistently across multiple jurisdictions.
Revenue Generation and Dual-Payer Funding
The Brisbane Empax Clinic has commenced treating insurer-funded patients, marking the company’s first revenue-generating clinical site on the East Coast. This validates the repeatability and scalability of Emyria’s treatment model across Australia. Complementing this, the Department of Veterans’ Affairs (DVA) has become the world’s first government payer to fund medication-assisted psychotherapy for eligible veterans with PTSD and treatment-resistant depression. This government funding complements existing Medibank pathways, establishing a unique dual-payer reimbursement framework that enhances revenue diversification and clinic-level economics.
Capital Raise Fuels Accelerated Growth
Emyria successfully completed an $8 million institutional placement at $0.06 per share, attracting strong demand from life-sciences and healthcare-focused investors. The proceeds will support rapid East Coast site development, expansion of the clinical workforce, and preparatory work for community-based programs targeting veterans and workers’ compensation patients in 2026. This capital injection strengthens Emyria’s balance sheet, enabling the company to transition from early validation to rapid multi-state execution of its national rollout strategy.
Outlook for Sustainable National Scale
With insurer-funded programs now operational in Western Australia and Queensland, and government funding secured for veterans, Emyria is well-positioned to meet growing demand for evidence-based, intensive mental-health treatments across Australia. The company’s capital-light, scalable clinic model and integrated data systems provide visibility over future growth while maintaining operational leverage. As new clinics come online and patient throughput increases, Emyria aims to establish predictable, recurring revenue streams that underpin long-term value creation.
Bottom Line?
Emyria’s strategic moves and funding boost set the stage for a rapid national rollout, but execution risks and reimbursement continuity remain key watchpoints.
Questions in the middle?
- How quickly will the Victorian Empax clinic move from negotiation to operational status?
- What impact will dual-payer funding have on patient volumes and revenue growth?
- Can Emyria maintain its capital-light model while scaling rapidly across multiple states?
